ライフサイエンスコーパス: specific immunotherapy

1 roteins can enhance the efficacy of allergen-specific immunotherapy.

2 tients during the build-up phase of allergen-specific immunotherapy.

3 ased in allergic patients receiving allergen-specific immunotherapy.

4 sponses to allergens and successful allergen-specific immunotherapy.

5 immunopathology and the clinical efficacy of specific immunotherapy.

6 promising vaccines for birch pollen allergen-specific immunotherapy.

7 ecules of P pratense previously proposed for specific immunotherapy.

8 ies, and have implications for diagnosis and specific immunotherapy.

9 prescribed routes for administering allergen-specific immunotherapy.

10 unctive therapy in conjunction with allergen-specific immunotherapy.

11 e gun has emerged as an important form of Ag-specific immunotherapy.

12 evaluated as immunogens to implement active specific immunotherapy.

13 nfiltrating T(reg) cells could enhance tumor-specific immunotherapy.

14 are distinguished by their susceptibility to specific immunotherapy.

15 a stratification factor targeted for active-specific immunotherapy.

16 boosting the patient's immune response using specific immunotherapy.

17 dditional evaluation as a target for antigen-specific immunotherapy.

18 nomas and also serves as a target for active-specific immunotherapy.

19 e assessment, antigen discovery, and antigen-specific immunotherapy.

20 that would normally escape killing by MART-1-specific immunotherapy.

21 malignancies and may be a target for antigen-specific immunotherapy.

22 vely, a tumor-associated antigen for active, specific immunotherapy.

23 solation of immunogenic antigens and antigen-specific immunotherapy.

24 otential targets for the induction of active specific immunotherapy.

25 is very important for the design of antigen-specific immunotherapy.

26 prostate cancers, is a potential target for specific immunotherapy.

27 can be used as potential targets for active-specific immunotherapy.

28 kes Graves' disease a prime candidate for Ag-specific immunotherapy.

29 atitis, and malaria vaccines and in allergen-specific immunotherapy.

30 This is also the case for specific immunotherapy.

31 improve the efficacy and safety of allergen-specific immunotherapy.

32 itization and determine its role in allergen-specific immunotherapy.

33 agnosis and offer the possibility of antigen-specific immunotherapy.

34 be considered an important component for HDM-specific immunotherapy.

35 al failed to demonstrate clinical benefit of specific immunotherapy.

36 lergen-derived epitopes change over allergen-specific immunotherapy.

37 nding is one important mechanism of allergen-specific immunotherapy.

38 re anaphylaxis management plans and allergen-specific immunotherapy.

39 serum concentrations enhances the benefit of specific immunotherapy.

40 igens and allergic patients before and after specific immunotherapy.

41 ) suggests this molecule as prime target for specific immunotherapy.

42 native to conventional subcutaneous allergen-specific immunotherapy.

43 gation to improve the efficacy and safety of specific immunotherapy.

44 clinical trials of several specific and non-specific immunotherapies.

45 ablished as a novel mechanism to escape CD19-specific immunotherapies.

46 cytokines need to be explored to design more specific immunotherapies.

47 esis of PV, with implications for developing specific immunotherapies.

48 oinflammatory is important for the design of specific immunotherapies.

49 Specific immunotherapy acts to modify the underlying cau

50 LT may be a promising strategy for allergen-specific immunotherapy against birch pollen allergy.

51 linical and clinical studies as a target for specific immunotherapy against gastrointestinal adenocar

52 ed to evaluate CEA as a potential target for specific immunotherapy against HNC.

53 n be further developed as patient- and tumor-specific immunotherapy against human lymphomas.

54 in patients with malignant glioma by active specific immunotherapy against these common MAAs.

55 disease pathogenesis and test novel TSHR Ag-specific immunotherapies aimed at curing Graves' disease

56 nd easy to manufacture vaccines for allergen-specific immunotherapy (AIT) has been limited by the poo

57 Allergen-specific immunotherapy (AIT) has been used for more than

58 Allergen-specific immunotherapy (AIT) induces specific blocking a

59 Allergen-specific immunotherapy (AIT) is the only available cause

60 While allergen-specific immunotherapy (AIT) is very efficient in hymeno

61 alth care cost savings conferred by allergen-specific immunotherapy (AIT) to US children with allergi

62 It is still unclear whether allergen-specific immunotherapy (AIT) with birch pollen improves

63 ant in long-term treatment, such as allergen-specific immunotherapy (AIT).

64 roposed as an alternative route for allergen-specific immunotherapy (AIT).

65 In the practice of antigen-specific immunotherapy, allergens or self antigens are r

66 Antigen-specific immunotherapy, an approach to selectively block

67 ise for treating tumors by combining antigen-specific immunotherapy and antiangiogenesis.

68 appear to play an important role in allergen-specific immunotherapy and could be an attractive target

69 basophils has been demonstrated in allergen-specific immunotherapy and drug desensitization.

70 actions are common in the course of allergen-specific immunotherapy and even occur with allergy vacci

71 As demonstrated in allergen-specific immunotherapy and in the healthy immune respons

72 OS and RFS achieved by active specific immunotherapy and low-dose IFN-alpha-2b were in

73 ected stage III melanoma administered active specific immunotherapy and low-dose interferon alfa-2b (

74 e findings support further development of E7-specific immunotherapy and strategies for up-regulation

75 e articles focused on mechanisms of allergen-specific immunotherapy and the development of novel anti

76 Th response to K as a key step in designing specific immunotherapy and understanding the immunogenic

77 me, identify patients likely to benefit from specific immunotherapies, and tailor combination immunot

78 ed since the first report describing antigen-specific immunotherapy (antigen-SIT) was published.

79 Improved methods of delivering peanut-specific immunotherapy are needed.

80 This promotes epitope specific immunotherapy as a possible safe treatment opti

81 nd we put forth the concept of focused organ-specific immunotherapy as an alternative option.

82 their increase during the course of allergen-specific immunotherapy, as well as their increased expre

83 des currently being investigated for antigen specific immunotherapy (ASI) of type 1 diabetes.

84 phase III clinical trial of adjuvant active specific immunotherapy (ASI) with an autologous tumor ce

85 st in testing whether the success of antigen-specific immunotherapy (ASIT) for autoimmune diseases in

86 Allergen-specific immunotherapy (ASIT) is used to treat the sympt

87 Successful antigen-specific immunotherapy (ASIT) would allow for improved t

88 the use as adjuvant and carrier in allergen-specific immunotherapy (ASIT).

89 of the major fish allergen, parvalbumin, for specific immunotherapy based on mutation of the 2 calciu

90 pment of a vaccine for grass pollen allergen-specific immunotherapy based on two recombinant hypoalle

91 However, subcutaneous allergen-specific immunotherapy can also induce anaphylaxis in so

92 Specific immunotherapy can greatly reduce the need for s

93 time, direct evidence in humans that antigen-specific immunotherapy can target not only antigen-posit

94 for multiple rV-CEA immunizations in active-specific immunotherapy clinical protocols directed at CE

95 Antigen-specific immunotherapy combats autoimmunity or allergy b

96 Active-specific immunotherapy could induce and/or augment the T

97 een made through the development of allergen-specific immunotherapy encompassing 3 major forms of tre

98 Recently, epicutaneous allergen-specific immunotherapy (EPIT) has proven effective, yet

99 Epicutaneous allergen-specific immunotherapy (EPIT) is proposed as an alternat

100 of our third trial on epicutaneous allergen-specific immunotherapy (EPIT) will be presented and disc

101 Epicutaneous allergen-specific immunotherapy (EPIT) with OVA and DCP also prot

102 ith mRNA isolated from tumor cells may allow specific immunotherapy even in cancers for which potent

103 effective immune modulator in several active-specific immunotherapy experimental protocols using eith

104 that arise postvaccination and following Ag-specific immunotherapies for cancer and autoimmune disea

105 in using this phenomenon to develop antigen-specific immunotherapies for T cell-mediated autoimmune

106 tripartite strategy provided potent antigen-specific immunotherapy for an aggressive established tum

107 ant epitope may allow development of antigen-specific immunotherapy for CD.

108 tential approach of tumor-specific G antigen-specific immunotherapy for cervical cancer.

109 Although specific immunotherapy for food allergies is becoming mo

110 pened unprecedented opportunities for active specific immunotherapy for melanoma with synthetic pepti

111 These findings describe a promising specific immunotherapy for patients with DR1-mediated au

112 od hypersensitivities worldwide but allergen-specific immunotherapy for shellfish allergy is not yet

113 Subcutaneous allergen-specific immunotherapy frequently causes allergic side e

114 Allergen specific immunotherapy has been shown to be the only eff

115 New strategies for allergen-specific immunotherapy have focused on reducing IgE reac

116 ells and therefore is a promising target for specific immunotherapies in AML.

117 aise important considerations for the use of specific immunotherapies in general.

118 Importantly, successful specific immunotherapy in allergic patients also induced

119 TL clones are promising reagents for antigen-specific immunotherapy in BMT hosts, because they engraf

120 nd LAGE-1 are attractive targets for antigen-specific immunotherapy in EOC.

121 -NPs might be a valuable strategy for peanut-specific immunotherapy in human subjects.

122 implications for clinical approaches to CTAg-specific immunotherapy in patients with cancer.

123 sents a useful immunogen to implement active specific immunotherapy in patients with melanoma, becaus

124 eactive serum IgGs after successful allergen-specific immunotherapy in patients.

125 The efficacy of single-allergen-specific immunotherapy in polysensitized subjects is a m

126 o induce immune deviation by mucosal peptide-specific immunotherapy in rheumatoid arthritis (RA) pati

127 ith malignant melanoma, vitiligo, and active-specific immunotherapy-induced depigmentation had signif

128 d to monitor the blocking effect of allergen-specific immunotherapy-induced non-IgE antibodies.

129 Induction of allergen tolerance through specific immunotherapy induces a specific expansion of t

130 Subcutaneous allergen-specific immunotherapy is a standard route for the immun

131 Sublingual allergen-specific immunotherapy is a viable alternative to subcut

132 r, neither a protective vaccine nor pathogen-specific immunotherapy is currently available.

133 Allergen-specific immunotherapy is helpful in IgE-mediated AR and

134 Allergen-specific immunotherapy is not currently undertaken for p

135 Efficacy of allergen-specific immunotherapy is often severely impaired by det

136 The main aim of specific immunotherapy is sustained effect due to change

137 The goal of allergen-specific immunotherapy is the induction of protective im

138 Allergen-specific immunotherapy is the only allergen-specific and

139 Allergen-specific immunotherapy is the only causative treatment o

140 Allergen-specific immunotherapy is the only curative treatment fo

141 Allergen-specific immunotherapy is the only known therapy that pr

142 Allergen-specific immunotherapy is the only mode of therapy that

143 An effective, nontoxic, tumor-specific immunotherapy is the ultimate goal in the battl

144 Finally, specific immunotherapy is under further investigation as

145 Human studies demonstrated that allergen-specific immunotherapy (IT) represents an effective trea

146 ponse of vitamin D as an adjunct to allergen-specific immunotherapy (IT).

147 iotics have not proved helpful, but allergen-specific immunotherapy may be disease modifying and ther

148 Antigen specific immunotherapy mediated via the sustained genera

149 on the clinical development of products for specific immunotherapy of allergic diseases do not adequ

150 tes immunotolerance, as, for example, during specific immunotherapy of allergies, but it mediates tis

151 epresents a highly interesting candidate for specific immunotherapy of birch pollen allergy.

152 prompted renewed efforts to develop antigen-specific immunotherapy of cancer.

153 s a candidate vaccine for gene-based antigen-specific immunotherapy of CML and may serve as a paradig

154 inant hypoallergenic combination vaccine for specific immunotherapy of HDM allergy.

155 be an essential component for diagnosis and specific immunotherapy of HDM allergy.

156 in developing efficient vaccines for antigen-specific immunotherapy of human malignancies.

157 To develop a specific immunotherapy of MG, we treated rats with ongoi

158 ign an altered peptide ligand, CGP77116, for specific immunotherapy of multiple sclerosis.

159 t be helpful to evaluate the effect of birch-specific immunotherapy on pollen-associated food allergi

160 ng T(H)2 cells and the influence of allergen specific immunotherapy on the phenotype and function of

161 rameters influencing the efficacy of antigen-specific immunotherapy once diabetes is established, pla

162 inistration of 25(OH)D in the context of OVA-specific immunotherapy reduced the allergic airway infla

163 OVA-specific immunotherapy reduced the humoral immune reacti

164 Finally, specific immunotherapy resulted in IL-5 down modulation,

165 Subcutaneous allergen-specific immunotherapy (SCIT) is a well-documented treat

166 native to conventional subcutaneous allergen-specific immunotherapy (SCIT).

167 These findings suggest that adjuvant active specific immunotherapy should be considered after cytore

168 Although subcutaneous allergen-specific immunotherapy showed no statistically significa

169 This antigen-specific immunotherapy significantly reduced both the in

170 Early events of specific immunotherapy (SIT) are induction of allergen-s

171 Allergen-specific immunotherapy (SIT) faces problems related to s

172 ating the role of CD4(+) T cells in allergen-specific immunotherapy (SIT) has been the absence of an

173 Specific immunotherapy (SIT) involves repeated treatment

174 Specific immunotherapy (SIT) is the most widely used tre

175 Specific immunotherapy (SIT) is the only treatment with

176 ere matched against an experimental allergen-specific immunotherapy (SIT) preparation containing Phl

177 cross-reacting molecules might hinder proper specific immunotherapy (SIT) prescription in polysensiti

178 Specific immunotherapy (SIT) represents an effective tre

179 he most effective treatment for allergies is specific immunotherapy (SIT), which involves the injecti

180 IgE- and T-cell-mediated side-effects during specific immunotherapy (SIT).

181 uisite for accurate prescription of allergen-specific immunotherapy (SIT).

182 from a patient who had received grass pollen-specific immunotherapy (SIT).

183 populations in patients with allergies after specific immunotherapy (SIT).

184 mbinant allergens offer a tool for improving specific immunotherapy (SIT).

185 lar diagnosis of, and for the development of specific immunotherapy strategies against, wheat food al

186 nhibited in standard NOD mice by autoantigen-specific immunotherapy targeting pathogenic CD8+ T-cells

187 00E) would suggest the feasibility of active specific immunotherapy targeting the mutation in these p

188 opportunity to subvert CMV antigens as tumor-specific immunotherapy targets.

189 sed as a safer hypoallergenic alternative in specific immunotherapy than the pollen extracts used tod

190 er a promising path for developing DC subset-specific immunotherapies that cannot be provided by tran

191 In 18 patients treated by Bet v 1-fragment-specific immunotherapy, the effects of IgG antibodies sp

192 Antigen-specific immunotherapy therefore offers disease interven

193 downregulated to some degree by conventional specific immunotherapy, this approach is only partially

194 onitoring the therapeutic efficacy of active specific immunotherapy toward specific MAA-bearing melan

195 Responses from specific immunotherapy treatment individuals were weaker

196 a function of seasonality, or as a result of specific immunotherapy treatment or varying disease seve

197 evaluate the efficacy and safety of allergen-specific immunotherapy using 2 dose regimens of Bet v 1

198 -gamma: Antitumor immunity induced by active-specific immunotherapy (vaccination) required IFN-gamma,

199 Specific immunotherapy via the subcutaneous or oral rout

200 Venom-specific immunotherapy (VIT) is well recognized by its e

201 Allergen-specific immunotherapy was associated with preferential

202 OVA-specific immunotherapy was established and studied in a

203 Active specific immunotherapy was injected subcutaneously (SC)

204 aspects of various antigen-specific and non-specific immunotherapies, which could potentially preven

205 r lymphocyte depletion prior to oral antigen-specific immunotherapy will likely be required to impart

206 sion emphasizes the need to implement active specific immunotherapy with a combination of peptides pr

207 eive either 2 years of treatment with active specific immunotherapy with allogeneic melanoma lysates

208 Specific immunotherapy with birch pollen (BP-SIT) induce

209 However, specific immunotherapy with birch pollen has inconsisten

210 Active-specific immunotherapy with dendritic cells loaded with

211 Allergen-specific immunotherapy with SHAS-OVA as compared to solu

212 efficacy and safety of subcutaneous allergen-specific immunotherapy with the use of depigmented polym